Nutriband Signs Agreement With Brand Institute to Develop the Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch
Nutriband (NASDAQ:NTRB / NTRBW) announced on October 10, 2025 that its 4P Therapeutics subsidiary signed an agreement with Brand Institute to develop the worldwide commercial brand name and visual identity for its lead product, the development-named AVERSA™ FENTANYL, an abuse-deterrent fentanyl transdermal system using AVERSA™ technology.
Brand Institute will provide naming and identity services and regulatory support via its Drug Safety Institute, leveraging prior experience with drug-name approvals and regulatory naming guidance.
Nutriband (NASDAQ:NTRB / NTRBW) ha annunciato il 10 ottobre 2025 che la sua controllata 4P Therapeutics ha firmato un accordo con per sviluppare il nome commerciale mondiale e l'identità visiva per il suo prodotto di punta, lo sviluppo-named AVERSA™ FENTANYL, un sistema transdermico di fentanyl deterrente all'abuso che utilizza la tecnologia AVERSA™.
Brand Institute fornirà servizi di naming e identità e supporto regolatorio tramite il suo Drug Safety Institute, sfruttando l'esperienza precedente con approvazioni di nomi di farmaci e linee guida regolamentari per l'assegnazione dei nomi.
Nutriband (NASDAQ:NTRB / NTRBW) anunció el 10 de octubre de 2025 que su subsidiaria 4P Therapeutics firmó un acuerdo con para desarrollar el nombre comercial mundial y la identidad visual de su producto principal, el AVERSA™ FENTANYL, aún en desarrollo, un sistema transdérmico de fentanilo disuasivo de abuso que utiliza la tecnología AVERSA™.
Brand Institute proporcionará servicios de nomenclatura e identidad y apoyo regulatorio a través de su Drug Safety Institute, aprovechando la experiencia previa con aprobaciones de nombres de fármacos y directrices regulatorias para la nomenclatura.
Nutriband (NASDAQ:NTRB / NTRBW)은 2025년 10월 10일에 자회사 4P Therapeutics가 Brand Institute와 전 세계 상업적 브랜드명 및 시각적 아이덴티티를 개발하기로 합의했다고 발표했습니다. 개발명 AVERSA™ FENTANYL은 AVERSA™ 기술을 사용하는 남용 억제 펜타닐 트랜스더말 시스템입니다.
Brand Institute는 Drug Safety Institute를 통해 명명 및 아이덴티티 서비스와 규제 지원을 제공하며, 의약명 승인 및 규제 명명 지침에 대한 이전 경험을 활용합니다.
Nutriband (NASDAQ:NTRB / NTRBW) a annoncé le 10 octobre 2025 que sa filiale 4P Therapeutics a signé un accord avec pour développer le nom commercial mondial et l'identité visuelle de son produit phare, le nom de travail AVERSA™ FENTANYL, un système transdermique de fentanyl anti-abus utilisant la technologie AVERSA™.
Brand Institute fournira des services de naming et d'identité et un soutien réglementaire via son Drug Safety Institute, tirant parti de l'expérience préalable en matière d'approbation des noms de médicaments et des directives réglementaires de dénomination.
Nutriband (NASDAQ:NTRB / NTRBW) kündigte am 10. Oktober 2025 an, dass seine Tochtergesellschaft 4P Therapeutics eine Vereinbarung mit Brand Institute unterzeichnet hat, um den weltweiten Handelsnamen und das visuelle Erscheinungsbild für sein führendes Produkt zu entwickeln, den Entwicklungsnamen AVERSA™ FENTANYL, ein missbrauchsdeterrentes Transdermalsystem mit Fentanyl, das AVERSA™-Technologie verwendet.
Brand Institute wird Namensgebung und Identität sowie regulatorische Unterstützung über sein Drug Safety Institute bereitstellen und dabei auf Erfahrungen mit Zulassungen von Medikamentennamen und regulatorischen Namensrichtlinien zurückgreifen.
Nutriband (NASDAQ:NTRB / NTRBW) أعلنت في 10 أكتوبر 2025 أن ابنتها الشركة 4P Therapeutics وقعت اتفاقاً مع Brand Institute لتطوير الاسم التجاري العالمي والهوية البصرية لمنتجها الرائد، AVERSA™ FENTANYL، وهو نظام عبر جلدي للفنتانيل ضد إساءة الاستخدام باستخدام تقنية AVERSA™.
ستوفر Brand Institute خدمات التسمية والهوية والدعم التنظيمي عبر معهد سلامة الأدوية Drug Safety Institute، مستفيدة من خبراتها السابقة في موافقات أسماء الأدوية وإرشادات التسمية التنظيمية.
Nutriband (NASDAQ:NTRB / NTRBW) 于 2025年10月10日宣布，其子公司 4P Therapeutics 已与 Brand Institute 签署协议，在全球范围内开发其主打产品的商业品牌名和视觉识别系统，该产品名为开发代号 AVERSA™ FENTANYL，是使用 AVERSA™ 技术的抑制滥用的芬太尼经皮给药系统。
Brand Institute 将通过其 Drug Safety Institute 提供命名与标识服务及监管支持，凭借在药品名批准和监管命名指南方面的经验。
- None.
- None.
Insights
Branding partnership advances commercial identity work for Nutriband's AVERSA™ FENTANYL; operational step, not a clinical or regulatory milestone.
Nutriband signed an agreement with Brand Institute, Inc. to develop the worldwide commercial brand name and visual identity for its lead product, the abuse‑deterrent fentanyl transdermal system currently called AVERSA™ FENTANYL. The engagement includes regulatory naming support from Drug Safety Institute, led by former agency officials, and leverages Brand Institute's stated market share of
The business mechanism is straightforward: secure a proprietary, distinguishable commercial name and identity to reduce look‑alike/sound‑alike medication errors and support downstream labeling and marketing steps. This activity does not itself change clinical, regulatory approval, or commercial viability facts; it is preparatory work focused on brand differentiation and regulatory name clearance.
Dependencies and risks are explicit and operational: successful regulatory clearance of the proposed proprietary name and visual identity, and subsequent clinical and regulatory approvals for the product itself. Watch for concrete regulatory filings and name submissions timelines, any FDA/USAN/EMA feedback from Drug Safety Institute, and announcements tied to clinical or marketing milestones over the next 12–24 months.
Nutriband initiates commercial worldwide brand name development for its lead product, an abuse deterrent transdermal system.
Nutriband has partnered with Brand Institute, Inc, the global leader in pharmaceutical and healthcare-related brand name and identity development.
ORLANDO, Fla., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that through its 4P Therapeutics subsidiary, it has signed an agreement with Brand Institute, Inc, the global leader in pharmaceutical and healthcare-related brand name and identity development services to develop the worldwide commercial brand name and visual identity for its lead product, an abuse deterrent fentanyl transdermal system. This product utilizes Nutriband’s AVERSA™ abuse deterrent transdermal technology and has the development name AVERSA™ FENTANYL.
AVERSA™ FENTANYL has the potential to be the world’s first abuse-deterrent opioid patch designed to deter abuse and misuse and reduce the risk of accidental exposure of opioids such as fentanyl.
Developing a proprietary brand name for a prescription drug product is a critical element in drug product development because the end users (doctors, pharmacists, patients) must be able to easily distinguish a proprietary name from other drug names that are phonetically similar (sound-alike names) or similar in their spelling or appearance (look-alike names). In addition, if the drug name is otherwise confusing or misleading, the patient might receive the wrong product and the subsequent medication error could lead to significant harm to the patient.
Brand Institute has been leading the market for over 20 years with a
Drug Safety Institute (DSI), a wholly owned regulatory subsidiary of Brand Institute, will provide regulatory services, solutions and support on the project. DSI is led by former officials from US Food & Drug Administration (FDA), European Medicines Agency (EMA), Health Canada (HC), United States Adopted Name Council (USAN), and World Health Organization (WHO) who co-authored the naming guidance documents while with their former respective agencies.
Nutriband’s AVERSA™ abuse-deterrent technology is utilized to incorporate aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential including opioids and stimulants. The AVERSA™ abuse deterrent technology is protected by a broad international intellectual property portfolio with patents issued in 46 countries including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.
About AVERSA™ Abuse-Deterrent Transdermal Technology
Nutriband's AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.
About Nutriband, Inc.
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.
About Brand Institute, Inc., and wholly owned regulatory subsidiary, Drug Safety Institute
Brand Institute is the global leader in pharmaceutical and healthcare-related name development, with a portfolio of over 5,000 marketed healthcare brand names and 1,800 USAN/INN nonproprietary names for nearly 1,600 clients. The company partners on over
Forward-Looking Statements
Certain statements contained in this press release, including, without limitation, statements containing the words ‘'believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Forms 10-K’s and Forms 10-Q’s, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.
Contact Information:
Nutriband Inc.
Phone: 407-377-6695
Email: info@nutriband.com
SOURCE: Nutriband Inc.
FAQ
What did Nutriband announce about AVERSA FENTANYL on October 10, 2025?
Which Nutriband subsidiary signed the naming agreement for NTRB's fentanyl patch?
What role will Drug Safety Institute play in the NTRB naming project?
What is AVERSA technology mentioned in the Nutriband announcement?
Does the press release state where Nutriband's AVERSA patents are issued?
How does Brand Institute position itself in pharmaceutical naming according to the announcement?
